- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 307/81 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
Patent holdings for IPC class C07D 307/81
Total number of patents in this class: 285
10-year publication summary
|
26
|
19
|
18
|
17
|
15
|
18
|
12
|
24
|
21
|
14
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2699 |
17 |
| Sanofi | 3995 |
12 |
| Janssen Pharmaceutica N.V. | 3438 |
10 |
| Vanda Pharmaceuticals, Inc. | 349 |
9 |
| Novartis AG | 10974 |
8 |
| Karyopharm Therapeutics Inc. | 142 |
6 |
| Tactogen Inc | 36 |
6 |
| Akaal Pharma Pty Ltd. | 11 |
5 |
| BioCryst Pharmaceuticals, Inc. | 175 |
5 |
| io Therapeutics, Inc. | 116 |
5 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 817 |
5 |
| Les Laboratoires Servier | 539 |
4 |
| vTv Therapeutics LLC | 152 |
4 |
| Vernalis (R&D) Limited | 134 |
4 |
| Ambient Photonics, Inc. | 15 |
4 |
| Genentech, Inc. | 3917 |
3 |
| Merck Patent GmbH | 5830 |
3 |
| Abbvie Inc. | 1786 |
3 |
| Antabio SAS | 22 |
3 |
| Aurimmed Pharma, Inc. | 7 |
3 |
| Other owners | 166 |